Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 2, 2011, Pages 223-230

  Bentzen, Bo Hjorth ^a,b   Bahrke, Sophia ^a   Wu, Kezhong ^a   Larsen, Anders Peter ^b   Odening, Katja E ^a   Franke, Gerlind ^a   Vańs Gravesande, Karin Storm ^a   Biermann, Jürgen ^a   Peng, Xuwen ^c   Koren, Gideon ^d   Zehender, Manfred ^a   Bode, Christoph ^a   Grunnet, Morten ^e   Brunner, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e NEUROSEARCH A S   (Denmark)

Author keywords

hERG; hERG activation; Kv11.1; long QT syndrome

Indexed keywords

1,3 BIS[2 HYDROXY 5 (TRIFLUOROMETHYL)PHENYL]UREA; CARDIOVASCULAR AGENT; NS 1643; POTASSIUM CHANNEL KV11.1; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; UREA DERIVATIVE; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; ELECTROSTIMULATION; EXPERIMENTAL RABBIT; FEMALE; GENOTYPE; HEART LEFT VENTRICLE; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART RATE; HEART VENTRICLE FIBRILLATION; ISOLATED HEART; LONG QT SYNDROME; LONG QT SYNDROME 1; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; TRANSGENIC ANIMAL;

ACTION POTENTIALS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CRESOLS; CROSS-OVER STUDIES; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; LONG QT SYNDROME; PHENYLUREA COMPOUNDS; RABBITS; RANDOM ALLOCATION;

EID: 79951549769     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318203a44d     Document Type: Article

References (21)

1. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet. 2008;372:750-763.
2. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment ''failures.'' Circulation. 2009;119:215-221.
3. Grunnet M, Hansen RS, Olesen SP. hERG1 channel activators: a new anti-arrhythmic principle. Prog Biophys Mol Biol. 2008;98:347-362.
4. Demolombe S, Lande G, Charpentier F, et al. Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part I: phenotypic characterisation. Cardiovasc Res. 2001;50:314-327. (Pubitemid 32382158)
5. Brunner M, Peng X, Liu GX, et al. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest. 2008;118:2246-2259. (Pubitemid 351872342)
6. Odening KE, Hyder O, Chaves L, et al. Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. Am J Physiol Heart Circ Physiol. 2008;295:H2264-H2272.
7. Diness TG, Yeh YH, Qi XY, et al. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res. 2008;79:61-69. (Pubitemid 351881940)
8. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002;87:220-228. (Pubitemid 34177674)
9. Carlsson L, Abrahamsson C, Drews L, et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation. 1992;85:1491-1500.
10. Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000;102:706-712. (Pubitemid 30640673)
11. Casis O, Olesen SP, Sanguinetti MC. Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol. 2006;69:658-665. (Pubitemid 43121963)
12. Hansen RS, Diness TG, Christ T, et al. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol. 2006;69:266-277. (Pubitemid 43048913)
13. Killeen MJ, Thomas G, Olesen SP, et al. Effects of potassium channel openers in the isolated perfused hypokalaemic murine heart. Acta Physiol (Oxf). 2008;193:25-36. (Pubitemid 351490258)
14. Tellez JO, Dobrzynski H, Greener ID, et al. Differential expression of ion channel transcripts in atrial muscle and sinoatrial node in rabbit. Circ Res. 2006;99:1384-1393. (Pubitemid 44949674)
15. Lei M, Honjo H, Kodama I, et al. Heterogeneous expression of the delayed-rectifier K+ currents i(K, r) and i(K, s) in rabbit sinoatrial node cells. J Physiol. 2001;535(pt 3):703-714. (Pubitemid 32894483)
16. Lengyel C, Iost N, Virag L, et al. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br J Pharmacol. 2001;132:101-110. (Pubitemid 32140472)
17. Larsen AP, Olesen SP, Grunnet M, et al. Pharmacological activation of IKr impairs conduction in guinea pig hearts. J Cardiovasc Electrophysiol. 2010;21:923-929.
18. Lu HR, Vlaminckx E, Hermans AN, et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol. 2008;154:1427-1438.
19. Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm. 2008;5:585-590.
20. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955-1961.
21. Baher A, Qu Z, Hayatdavoudi A, et al. Short-term cardiac memory and mother rotor fibrillation. Am J Physiol Heart Circ Physiol. 2007;292: H180-H189. (Pubitemid 46105177)